Feedback / Questions
WP1122 - Moleculin, CNS Pharma, WPD Pharma
https://www.prnewswire.com/news-releases/moleculin-receives-fda-allowance-to-begin-a-phase-1-study-of-wp1122-for-the-treatment-of-glioblastoma-multiforme-301434546.html
Dec 1, 2021
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next